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Management of ovarian cancer: referral to a multidisciplinary team
matters
E.J. Junor, D.J. Hole & C.R. Gillis
West ofScotland Cancer Surveillance Unit, Ruchill Hospital, Glasgow G20 9NB, UK.
Smmary Differences in survival outcome for patients with ovarian cancer in Scotland led to an investigation
of whether these differences were due to variation in presenting prognostic features or to the organisation and
delivery of cancer services. A retrospective study of all 533 cases of ovarian cancer registered in Scotland in
1987 was carried out. After adjustment for age, stage, pathology, degree of differentiation and presence of
ascites, survival improved when patients (1) were first seen by a gynaecologist (P<0.05); (2) were operated on
by a gynaecologist (P<0.05); (3) had residual disease of less than 2 cm post-operatively (P<0.001); (4) were
prescribed platinum chemotherapy (P<0.05); and (5) were referred to a joint clinic (P<O.001). When
gynaecologists operated the likelihood of smaller residual disease increased (P<0.001). The improved survival
from management by a multidisciplinary team at a joint clinic was not solely due to the prescription of
platinum chemotherapy. The results of this study support the contents of the 1991 Department of Health
report on present acceptable practice in the management of ovarian cancer, circulated to gynaecologists and
surgeons in Scotland in 1992. The new finding that in a common cancer management by a multidisciplinary
team at a joint clinic directly affects survival requires urgent attention.
Survival for patients with ovarian cancer is improving
(Balvert-Locht et al., 1991; Ries et al., 1991; Black et al.,
1993). In the west of Scotland, 3 year survival for patients
under 55 years of age diagnosed between 1975 and 1988
improved from 36% to 50%. Patients aged 55-64 years
showed a survival improvement from 23% to 29% over the
same time period (Gillis et al., 1991). Patients treated in
teaching hospitals appeared to survive longer than those
treated elsewhere. These differences were increasing with time
(Gillis et al., 1991). However, not all teaching hospitals
offered a better outcome nor were all non-teaching hospitals
associated with a poorer outcome (Hole & Gillis, 1993).
This analysis (Gillis et al., 1991) was based on cancer
registration data, which included age and pathology but no
other major prognostic factors. This raised the question of
the extent to which other prognostic factors (e.g. stage,
degree of differentiation, ascites) or the type of treatment
carried out contributed to the differences in survival
observed.
A detailed study of all cases of ovarian cancer diagnosed in
the Scottish population in 1987 was carried out to identify
variations in patient management which might influence sur-
vival. The study investigated patients' referral patterns, their
treatment and outcome taking account of the above prognos-
tic factors.
Patients and methods
Each of the 533 patients registered by the Scottish cancer
registration scheme with ovarian cancer diagnosed in 1987
was identified. Permission to scrutinise their case records was
obtained from their consultants. Thirty-four patients were
excluded because of incorrect pathology, year of diagnosis or
no information other than a death certificate. The medical
records of a further 20 patients could not be found.
Detailed information on presenting features, investigations,
pathology, stage, operative procedures, volume of residual
disease and subsequent referral and management for the
remaining 479 patients (Table I) was abstracted from the case
records. Information included details on the specialty of the
clinician to whom the patient was referred initially, the
specialty of the surgeon performing the initial operation and
multidisciplinary management at a joint clinic. Missing or
insufficiently detailed information was allocated to a not
known category. All patients were flagged with the Registrar
General (Scotland) for cause and date ofdeath. All deaths up
to 31 December 1992 were included, providing 5 years of
follow-up for each patient.
All histological reports were examined by one investigator
(E.J.) and coded according to the International Classification
of Disease for Oncology (WHO, 1976). No independent histo-
logical review was performed.
Staging was performed by one of the authors (E.J.) using
the standard FIGO (International Federation of Gynae-
cology and Obstetrics) classification on the basis of the oper-
ation note, pathology report and the results of all available
investigations.
Chemotherapy comprised either platinum (cis- or carbo-
platin), an alkylating agent, a combination of platinum with
an alkylating agent or no chemotherapy. For the analysis all
patients receiving a platinum drug with or without other
agents were called the platinum group; those receiving an
alkylating agent alone constituted the alkylating group; the
rest made up the no chemotherapy group.
A joint clinic was defined as one in which gynaecologists
and oncologists agreed the most appropriate management
throughout the entire post-operative treatment.
st a a sis
Cox's proportional hazards model was used to quantify the
effect of clinical management on survival, taking account of
prognostic factors (Cox, 1972).
The effects of different referral routes were estimated
separately from the outcomes of treatment in the following
manner. Firstly, a model using only those prognostic
variables found to be significant (age, stage, degree of
differentiation, histological type and presence of ascites) was
fitted (Table II). Secondly, variables relating to patients'
referral routes (who first saw them, who operated and atten-
dance at a combined clinic) were added (Table III). Thirdly,
treatment variables (amount of residual disease after oper-
ation and use of chemotherapy) were considered in addition
to those factors included in the first model (Table IV). Fac-
tors relating to patients' referral routes were not included in
this third model.
The histological types were reduced from 11 to three on
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the basis of their individual 5 year survival rates in this
study. This meant that borderline and germ cell tumours
were classified as good; mucinous and serous cystadenocar-
cinoma and endometrioid, mesonephroid, granulosa cell and
miscellaneous tumours were classified as moderate; and
adenocarcinoma (no subtype specifically stated) and mixed
mesodermal and unknown tumours were classified as poor.
Each of the other variables was treated as a categorical
variable with a specific category included for missing or
unknown information. The category with the largest number
of cases was chosen as the baseline in the Cox's proportional
hazards analysis.
Comparison of the volume of disease remaining (>or
<2 cm) in relation to the specialty of the surgeon perform-
ing the operation while simultaneously adjusting for age,
stage, degree of differentiation, pathological type and
presence of ascites was carried out using logistic regression
(Cox, 1970). A similar approach was used to find what
influenced the prescription of platinum chemotherapy. This
included using the volume of residual disease in addition to
age, stage, degree of differentiation, pathological type and
presence of ascites.
Resuts
Survival
Patients' characteristics and unadjusted 5 year survival rates
are shown in Table I. The overall 5 year survival rate for the
cohort was 23.6% (relative 5 year survival = 27.4%); 62.8%
of patients with ovarian cancer presented with advanced
disease (stage Ill or IV) and 63.2% had poorly differentiated
tumours. Adenocarcinoma (no subtype spified) was the
most common histological type. Each of these prognostic
factors was associated with 5 year survival of 14% or less.
Ascites was present in 24.0% of patients; 33.8% of patients
were admitted as emergency cases. Insufficient or missing
information meant that 27 (5.6%) patients could not be
staged, 158 (33.0%) patients had no recorded degree of
histological differentiation, 15 (3.1%) patients had no
recorded histological type and in 13 (2.7%) patients no
ascites status was given.
The results of the Cox's proportional hazards analysis
relating the risk of death to the five significnt prognostic
factors is shown in Table H, to the three 'referral' variables
(who initially saw the patient, the specialty ofthe person who
performed the operation and whether referral to ajoint clinic
took place) in Table mI and to the two 'treatment' variables
(amount of residual di remaining after operation and
the use of platinum) in Table IV. The effects described in
Tables III and IV are estimated after adjustment for the five
prognostic factors.
The risk of death increased significantly with later stage of
presentation (P<0.001), increasing age (P<0.001), poorer
histological differentiation (P<0.01), poor pathological type
(P<0.001) and presence of ascites (P<0.01). The risk of
death was no greater for patients admitted as emergencies
after adjustment for the five prognostic factors just men-
tioned.
Table I Patient charactenisics and unadjusted survival for ovarian cancer patients
diagnosed in Scotland in 1987
Number (%)' Percentage swrving
Characteristic of cases I year 3 years 5 years
All patients 479 54 30 24
Stage
119 (26.3) 92 77 66
II 49 (10.8) 61 41 33
III 212 (46.9) 46 15 8
IV 72 (15.9) 31 4 0
Not known 27 4 0 0
Age group
<45 39 (8.1) 82 67 56
45-54 85 (17.7) 67 40 29
55-64 133 (27.8) 61 32 24
65-74 129 (26.9) 51 26 20
75+ 93 (19.4) 25 12 9
Degree of differentiation
Well 40 (12.5) 70 60 55
Moderate 78 (24.3) 60 35 28
Poor 203 (63.2) 50 22 14
Not known 158 53 32 26
Presence of ascites
No 354 (76.0) 60 36 29
Yes 112 (24.0) 35 12 6
Not known 13 69 46 23
Histological type
Borderline 12 (2.6) 100 92 83
Germ cell 5 (1.1) 100 80 80
Mucinous adenocarcinoma 71 (15.3) 72 52 46
Serous adenocarcinoma 123 (26.5) 65 34 25
Endometrioid 34 (7.3) 59 44 35
Mesonephroid 19 (4.1) 47 37 32
Granulosa cell 7 (1.5) 100 57 57
Adenocarcinoma 176 (37.9) 38 13 7
Mixed mesodermal 12 (2.6) 25 8 0
Miscellaneous 5 (1.1) 60 40 0
Not known 15 13 0 0
Mode of admission
Elective 303 (66.2) 60 34 26
Emergency 155 (33.8) 44 25 21
Not known 21 38 24 14
'Percentages have been calmlated excluding the 'not knowns'.MULTIDISCIPLINARY MANAGEMENT OF OVARIAN CANCER 365
Table Relation betwen prognostic factors and survival amongst ovaran cancer
patients dignosed in 1987 in Scotland
Nunber of
Number of deaths in Relative hazard 95% confide
patients 5 years ratio (RHR) interval
Stage
I 119 40 0.28 0.18-0.40
II 49 33 0.77 0.53-1.14
IH 212 194 1 Baseine
IV 72 72 1.64 1.24-2.16
Not known 27 27 1.29 0.88-1.90
Test for trend t=6.38 (P<0.001)
Age group
<45 39 17 0.65 0.38-1.11
45-54 85 60 0.85 0.62-1.18
55-64 133 101 1 Baseine
65-74 129 103 1.17 0.88-1.55
75+ 93 85 2.02 1.50-2.72
Test for trend t=5.37 (P<0.001)
Degree of differentiation
Well 40 18 0.50 0.30-0.82
Moderate 78 56 0.75 0.55-1.02
Poor 203 175 1 Baseline
Not known 158 117 0.95 0.75-1.22
Test for trend t = 3.02 (P<0.01)
Pathological prognosis
Good 17 3 0.34 0.10-1.10
Moderate 259 173 1 Baseline
Poor 203 190 1.61 1.28-2.02
Test for trend t=4.56 (P<0.001)
Ascites
No 354 251 1 Baseline
Yes 112 105 1.56* 1.23-1.98
*P<0.01.
Tab HI Influence of 'referral' factors on survival after adjustment for the five
biological factors shown in Table II
Number of 95%
Nwnber of deaths in Relative confidence
patients 5 years hazard ratio interval
Who first saw patient?
Gynaccologist 231 150 1 Baseline
Non-gynaecologist 248 216 1.34* 1.05-1.70
Who performed operation?
Gynaccologist 367 263 1 Basehne
Surgeon 65 56 1.37* 1.05-1.77
Attendance at combined clinic
Yes 130 84 0.60** 0.46-0.78
No 349 282 1 Baseine
*P<0.05; **P<0.001.
Table IV Relationship of 'treatment' factors on survival after adjustment for the five
biological factors shown in Table II
Nwmber of 95%
Nwmber of deaths in Relatiee confidence
patients 5 years hazard ratio interval
Residual disea
<2 cm 184 89 0.50** 0.37-0.66
>2 cm 222 214 1 Baseline
Use of chemotherapeutic drugs
Platinum 158 128 0.72* 0.53-0.97
Alatin 137 103 1 Baseine
No chemotherapy 184 135 1.74** 1.33-2.29
*P<0.05; **P<0.001.366 E.J. JUNOR et al.
Improved survival was associated with three variables
relating to referral (Table III). These were: when the patient
was initially seen by a gynaecologist (P<0.05), when a
gunaecologist performed the operation (P <0.05) and atten-
dance at a joint clinic (P<0.001). Other factors which were
examined and were not related to survival were type and
duration of symptoms, time from presentation to hospital
referral and time from presentation to laparotomy.
Improved survival was associated with two variables
relating to treatment (Table IV). These were residual disease
less than 2 cm (P<0.001) and receiving platinum
chemotherapy (P<0.05). All these effects were apparent
after adjustment for the five prognostic factors age, stage,
degree of differentiation, histology and presence of ascites.
This latter analysis was repeated excluding patients who were
stage Ia or lb as well as those over 75 years of age (the
categories unlikely to be considered for platinum
chemotherapy in 1987) and showed the use of platinum still
to be associated with a greater improvement in survival
(P<0.01).
First contact with hospital
A total of 155 (33.8%) patients were initially admitted as
emergencies, while 303 (66.2%) patients were referred to an
outpatient clinic.
A total of 231 (48.2%) patients were seen first by a
gynaecologist, 167 (34.9%) by a surgeon and 65 (13.6%) by a
physician. Patients initially referred to surgeons and
physicians were older and had more advanced disease than
patients initially seen by gynaecologists (Table V). The 5 year
survival for those patients seen initially by a gynaecologist
was 35% compared with 16% for those seen by a non-
gynaecologist. This difference reduced from 27% to 21%
after adjustment for age and stage.
Operative procedures
A total of 432 (90.2%) patients underwent laparotomy, 367
by gynaecologists and 65 by general surgeons. Patients
operated on by surgeons were older (50.8% were aged 65 and
over compared with 40.9% for gynaecologists) and had more
advanced stage disease (72.3% were stage III or IV compared
with 57.5% for gynaecologists) (Table VI). The 5 year sur-
vival rate for those patients operated on by a gynaecologist
was 28% compared with 14% for those operated on by a
general surgeon. This difference reduced to 27% against 19%
after adjustment for age and stage. Table VII describes the
types of operation performed by gynaecologists and surgeons
and the extent of debulking. Total abdominal hysterectomy
bilateral salpingo-oopherectomy (TAHBSO) with or without
omentectomy was not used in patients with early-stage
disease and in only 4/47 (8.5%) patients with late-stage
disease when the operation was performed by a general
surgeon. This compared with 119/155 (76.8%) patients with
early-stage disease and 79/211 (37.4%) patients with late-
stage disease when the operation was performed by a gynae-
cologist. Only a small part of this difference was due to the
general surgeons operating on older patients. Optimal debul-
king was achieved more often when the operation was per-
formed by a gynaecologist, and this seemed to be a consistent
finding for both early and late stage and for younger and
older patients (Table VII). The extent of residual disease was
not stated in 21/366 (5.7%) staged patients who were
operated on by a gynaecologist and in 7/60 (11.7%) staged
patients who were operated on by a general surgeon.
Table VIII shows the relationship between the extent of
residual disease post-operatively, the specialty of the person
who performed the operation and the presenting factors age,
stage, degree of differentiation, pathological type and
presence of ascites. Gynaecologists were considerably more
successful at reducing the volume ofdisease (P<0.001), even
after adjustment for the five presenting factors just men-
tioned. This applied to both early (P<0.01) and late
(P<0.01) stage disease. Stage, age and pathological type
affected the probability of disease removal, but degree of
histological differentiation and the presence of ascites were
not independently associated (Table VIII).
Table V Characteristics of patients first seen by gynaecologists, surgeons and
physicians
Number (%) ofpatients first seen by a:
Gynaecologists Surgeon Physician Othere
(n = 231) (n = 167) (n = 65) (n = 16)
Stage
I and II 120 (51.9) 33 (19.8) 10 (15.4) 5 (31.3)
III and IV 109 (47.2) 119 (71.3) 48 (73.8) 8 (50.0)
Not known 2 (0.9) 15 (9.0) 7 (10.8) 3 (18.8)
Age
<45 30 (13.0) 4 (2.4) 4 (6.2) 1 (6.3)
45-64 113 (48.9) 76 (45.5) 21 (32.3) 8 (50.0)
65+ 88 (38.1) 87 (52.1) 40 (61.5) 7 (43.8)
Degree of differentiation
Well 30 (13.0) 8 (4.8) 2 (3.1) 0 (0.0)
Moderate 36 (15.6) 29 (17.4) 12 (18.5) 1 (6.3)
Poor 91 (39.4) 74 (44.3) 31 (47.7) 7 (43.8)
Not known 74 (32.0) 56 (33.5) 20 (30.8) 8 (50.0)
Pathological prognosis
Good 12 (5.2) 3 (1.8) 2 (3.1) 0 (0.0)
Moderate 152 (65.8) 75 (44.9) 25 (38.5) 7 (43.8)
Poor 67 (29.0) 89 (53.3) 38 (58.5) 9 (56.3)
Presence of ascites
No 191 (82.7) 112 (67.1) 42 (64.6) 9 (56.3)
Yes 32 (13.9) 52 (31.1) 22 (33.8) 6 (37.5)
Not known 8 (3.5) 3 (1.8) 1 (1.5) 1 (6.3)
Mode of admission
Elective 181 (78.4) 89 (53.3) 30 (46.2) 3 (18.8)
Emergency 46 (19.9) 74 (44.3) 32 (49.2) 3 (18.8)
Not stated 4 (1.7) 4 (2.4) 3 (4.6) 10 (62.5)
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Post-operative referral
A total of 130 (27.1%) patients were referred post-opera-
tively to a combined clinic. Age and pathological type were
the main determinants of whether a patient was referred.
Thirty-eight per cent (98/257) of patients under 65 years were
referred, compared with 14% (32/222) of those aged 65 and
over (Table DC).
Age and stage were the major determinants of both
whether patients received platinum chemotherapy or any
chemotherapy at all (Table X): 50.2% of patients under 65
years of age received platinum chemotherapy, compared with
20.2% of patients aged between 65 and 74 years.
Table XI shows the factors influencing the likelihood of
being treated with platinum. The analysis excluded those
patients 75 years of age and over and those staged Ia or lb.
Patients attending ajoint clinic were twice as likely to receive
platinum (P<0.01) as those who did not attend, even after
adjustment for age, stage, degree of differentiation,
pathological type, presence of ascites and extent of residual
diseaw. When the analysis was further restrcted to only
those patients who received some form ofchemotherapy (i.e.
an alkylating agent or some form of platinum), patients
attending a joint clinic were still almost twice as likely
(relative probability= 1.90, P=0.07) to receive platinum.
No attempt was made to relate the dose of the drug to
outcome.
Table VI Characteristics of patients operated on by gynaecologists
and surgeons
Patients operated on by:
Gynaecologists Surgeon No operation
(n = 367) (n = 65) (n =47)
Stage
I and II 155 (42.2) 13 (20.0) 0 (0.0)
III and IV 211 (57.5) 47 (72.3) 26 (55.3)
Not known 1 (0.3) 5 (7.7) 21 (44.7)
Age
<45 38 (10.4) 1 (1.5) 0 (0.0)
45-64 179 (48.8) 31 (47.7) 8 (17.0)
65+ 150 (40.9) 33 (50.8) 39 (83.0)
Degree of differentiation
Well 36 (9.8) 4 (6.2) 0 (0.0)
Moderate 61 (16.6) 14 (21.5) 3 (6.4)
Poor 165 (45.0) 26 (40.0) 12 (25.5)
Not known 105 (28.6) 21 (32.3) 32 (68.1)
Pathological prognosis
Good 16 (4.4) 1 (1.5) 0 (0.0)
Moderate 224 (61.0) 31 (47.7) 4 (8.5)
Poor 127 (34.6) 33 (50.8) 43 (91.5)
Presence of ascites
Yes 77 (21.0) 14 (21.5) 21 (44.7)
No 279 (76.0) 49 (75.4) 26 (55.3)
Not known 11 (3.0) 2 (3.1) 0 (0.0)
Mode of admission
Ekctive 254 (69.2) 36 (55.4) 13 (27.7)
Emergency 99 (27.0) 26 (40.0) 30 (63.8)
Not known 14 (3.8) 3 (4.6) 4 (8.5)
Table VII Types of operation and extent of residual disease after operation by
gynaecologists and surgeons (excludes six patients with unknown stage)
Who performed operation
Gvnaecologist Surgeon
Stage Stage
I1i I!IIV III IIIIV
(n = 155) (n = 211) (n = 13) (n =47
Type of operation
TAHBSO and omentectomy 63 (40.6) 68 (32.2) 0 (0.0) 2 (4.3)
TAHBSO 56 (36.1) 11 (5.2) 0 (0.0) 2 (4.3)
Bilateral oopherectomy+ 7 (4.5) 23 (10.9) 0 (0.0) 2 (4.3)
omentectomy
Bilateral oopherectomy 9 (5.8) 22 (10.4) 2 (15.4) 1 (2.1)
Oopherectomy 12 (7.8) 25 (11.8) 9 (69.2) 6 (12.8)
Omentectomy 0 (0.0) 5 (2.4) 0 (0.0) 1 (2.1)
Biopsy 6 (3.9) 55 (26.1) 2 (15.4) 33 (70.2)
Other 2 (1.3) 2 (0.9) 0 (0.0) 0 (0.0)
Percentage with <2cm remaining after operation
Aged <65 years 92.6 30.4 75.0 5.0
(87/94) (351115) (3/4) (1/20) Aged 65+ years 85.1 15.7 75.0 4.0
(40/47) (14/89) (3/4) (1/25)368 EJ. JUNOR et al.
Table VIII Relationship between the likelihood of diseas <2 cm
remaining after operation, the five presenting factors and the
specialty of the person performing the primary operation
Number of Rekztive0 95% confidence
Factor cases probability interval
Stage
I 101 14.6 7.1-30.1
II 48 5.6 2.5-12.3
III 195 1 Baseline
IV 55 0.5 0.2-1.1
Not known 5
c
Test for trend t=8.02 (P<0.001)
Age
<45 38 2.5 0.8-8.2
45-64 197 1 Baseline
65+ 169 0.5 0.3-0.9
Test for trend t=3.44 (P<0.001)
Degree of differentiation
Well 36 1.3 0.5-3.4
Moderate 72 1.1 0.5-2.4
Poor 182 1 Baseline
Not known 114 0.7 0.3-1.3
Test for trend t = 1.05 (NS)
Pathological type
Good 16 3.9 0.4-42.8
Moderate 236 1 Baseline
Poor 152 0.5 0.3-0.9
Test for trend t=3.05 (P<0.01)
Presence of ascites
No 304 1 Baseline
Yes 88 0.7 0.4-1.4
Who performed operation?
Gynaccologist 346 1 Baseline
Surgeon 57 0.2* 0.1-0.6
aExchuixng 47 patients who had no operation and 28 patients with
no statement on the extent of residual disease. tiTis figure is the
probability that a patient with the characeristic given will have
residual disease of less than 2cm after operation relative to the
probability for a patient with the basine characterstic. This has
been denved after adjusting for each of the other biological factors.
cnsufficient cases to allow estimation. *P<0.01.
Table IX Characteristics of patients attending joint clinics
Attendance at a joint clinic
Yes (n = 130) No (n = 349) Total
Stage
I and II 56 (33.3) 112 (66.7) 168
In and IV 73 (25.7) 211 (74.3) 284
Not known 1 26
Age (years)
<45 22 (56.4) 17 (43.6) 39
45-64 76 (34.9) 142 (65.1) 218
65+ 32 (14.4) 173 (85.6) 222
Degree of differentiation
Well 20 (50.0) 20 (50.0) 40
Moderate 18 (23.1) 60 (76.9) 78
Poor 61 (30.0) 142 (70.0) 203
Not known 31 127 158
Pathological prognosis
Good 12 (70.6) 5 (29.4) 17
Moderate 86 (33.2) 173 (66.8) 259
Poor 32 (15.8) 171 (84.2) 203
Presence of ascites
No 102 (28.8) 252 (71.2) 354
Yes 20 (17.9) 92 (82.1) 112
Not known 8 5 13
Extent of residual disease
<2cm 70 (38.0) 114 (62.0) 184
>2cm 51 (23.0) 171 (77.0) 222
Not known 9 64 73
Table X Characteristics of patients receiving chemotherapy
Chenotherapy given
Platinwn Alkylatng agent None
(n= 158) (n= 137) (n= 184)
Stage
I 20 (16.8) 36 (30.3) 63 (52.9) 119
II 19 (38.8) 16 (32.7) 14 (28.6) 49
III 87 (41.0) 61 (28.8) 64 (30.2) 212
IV 31 (43.1) 20 (27.8) 21 (29.2) 72
Not significant 1 4 22 27
Age (years)
<65 129 (50.2) 52 (20.2) 76 (29.6) 257
65-74 26 (20.2) 53 (41.1) 50 (38.8) 129
75+ 3 (3.2) 32 (34.4) 58 (62.4) 93
Degree of differentiation
Well 14 (35-0) 6 (15.0) 20 (50.0) 40
Moderate 24 (30.8) 31 (39.7) 23 (29.5) 78
Poor 88 (43.3) 54 (26.6) 61 (30.0) 203
Not known 32 46 80 158
Pathological prognosis
Good 2 (11.8) 0 (0.0) 15 (88.2) 17
Moderate 98 (37.8) 74 (28.6) 87 (33.6) 259
Poor 58 (28.6) 63 (31.0) 82 (40.4) 203
Presence of ascites
No 119 (33.6) 99 (28.0) 136 (38.4) 354
Yes 32 (28.6) 36 (32.1) 44 (39.3) 112
Not known 7 2 4 13
Extent of residual disease
<2cm 65 (35.3) 50 (27.2) 69 (37.5) 184
>2cm 88 (39.6) 70 (31.5) 64 (28.8) 222
Not significant 5 17 51 73
Attendance at a joint clinic
Yes 77 (59.2) 28 (21.5) 25 (19.2) 130
No 81 (23.2) 109 (31.2) 159 (45.6) 349
Table XI Relationship between the likelihood of receiving platinum,
the five presenting factors, extent of residual disease and attendance
at a joint clinic (excluding patients aged 75 years and over or stage
Ia, Tb)
Nwnber of Relative 95% confidence
Factor cases probabilities interval
Stage
I 56 0.14 0.05-0.34
II 42 0.36 0.15-0.88
III 164 1 Baseline
Iv 58 1.40 0.69-2.88
Not known 13 0.21 0.06-0.73
Test for trend t=3.98 P<0.001
Age
<45 29 1.54 0.55-4.34
45-64 191 1 Baseline
65-74 113 0.20 0.11 -0.35
Test for trend t=4.45 P<0.001
Degree of differentiation
Well 21 1.23 0.39-3.90
Moderate 52 0.69 0.33-1.44
Poor 162 1 Baseline
Not known 98 0.43 0.23-0.79
Test for trend t = 0.40 P = not significant
Pathological type
Good 7 0.32 0.04-2.45
Moderate 184 1 Baseline
Poor 142 0.52 0.30-0.92
Test for trend t= 1.30 P= not significant
Presence of ascites
Yes 76 1 Baseline
No 246 1.29 0.69-2.41
Extent of residual disease
<2 cm 177 1 Baseline
>2 cm 122 1.64 0.84-3.22
Attendance at a joint clinic
Yes 102 2.02* 1.13-3.60
No 231 1 Baseline
*P<0.05.MULTIDISCIPLINARY MANAGEMENT OF OVARIAN CANCER 369
This study provides evidence that improvement in 5 year
survival is associated with:
0
0
0
0
being seen initially by a gynaecologist;
being operated upon by a gynaecologist;
having debulking surgery to <2cm;
receiving platinum chemotherapy;
and being managed in a multidisciplinary combined
clinic.
Evidence has existed for some time that participation in
clinical trials (Lennox et al., 1975; Davis et al., 1985; Kar-
jalainen & Palva, 1989; Stiller & Draper, 1989) and referral
to specialist centres (Stiller, 1988; Karjaainen, 1990, Harding
et al., 1993) confer survival advantage on patients with cer-
tain types of cancer. These benefits have been seen in the
treatment of childhood cancers (Lennox et al., 1975; Stiller,
1988; Stiller & Draper, 1989), teratoma (Harding et al.,
1993), multiple myeloma (Karjalainen & Palva, 1989), non-
small-cell lung cancer (Davis et al., 1985) and breast cancer
(Karjalaien, 1990). Our study has identified specific aspects
of the clinical management of ovarian cancer which are
associated with improved survival. The advantage of debulk-
ing surgery has been known for some time (Griffiths, 1975).
The Medical Rearch Council overview has highlighted the
usefulness of platinum (Advanced Ovarian Cancer Trialists
Group, 1991). Now results on three other factors - being
seen initially by a gynaecologist, being operated on by a
gynaecologist and being referred to a multidisciplinary com-
bined clnic - are reported for the first time.
Three main management factors influence the overall out-
come of any disease process - making the correct diagnosis,
deciding on the most effective treatment and implementing
treatment.
Despite ovarian cancer being a gynaecological malignancy,
paradoxically more than 50% of patients were first seen by
surgeons or physicians. Ovarian cancer was suspected in 80%
of patients seen initially by gynaecologists compared with
43% of those seen by surgeons and 39% seen by physicians.
Further analysis of the data showed that only gynaecologists
routinely performed vaginal examinations and, while
surgeons preferred to examine the pelvis by the rectal route,
physcians were less likely to perform any pelvic examination.
Gynaecologists may be quicker to diagnose ovarian cancer
and more likely to implement present preferred treatment.
Surgeons were very unlikely to perform a total abdominal
hysterectomy and bilateral salpingoophorectomy. In the
majority of cases they performed only a biopsy. Thus their
patients were less likely to have residual disease of less than
2 cm remaining after operation (P<0.001), even after adjust-
ment for the presenting prognostic factors of age, stage,
degree of differentiation, pathological type and presence of
ascites. It is recognised that it may be easier to debulk some
tumours which inherently have a better prognosis than others
in which removal of the tumour is technically impossible.
However, it is unlikely that this could entirely explain the
5-fold difference in the likelihood of tumour reduction
associated with the specialty of the person performing the
operation (Table VIII).
Perhaps the most important finding of this study is that
management in a multidisciplinary combined clinic conferred
a highly significnt survival advantage (P<0.001). One ex-
planation for this could have been that patients attending a
combined clinic were more likely to receive platinum chemo-
therapy, as shown in Table XI. However, an additional
analysis including both these effects in the same model sug-
gested that this was only part of the reason. Improved sur-
vival associated with managemet by a multidisciplinary
team at a joint clinic remained significant (RHR = 0.73,
P<0.01) after allowing for the effect of prescribing platinum
chemotherapy. Thus there appeared to be an independent
benefit resulting from the involvement of a number of inter-
ested dinidans of different specialties in the managent of
the disease even at this later stage.
The role of selection in the patients' referral through the
clinical management system can clearly be a strong con-
founding factor. We have examined a large number of pre-
senting signs, symptoms and other factors to identify all
those which mightinfunce the clinical course of the disease.
Age, stage, degree of differentiation, pathological type and
presence of ascites all show an independent relationship with
survival as measured by Cox's proportional hazards model.
All five cinical manag nt effects found in this study were
statstically significant after adjustment for the presenting
prognostic factors (Tables mI and IV). This minimise any
confounding effect due to selection.
One prognostic factor we were unable to record in this
study because of insufficient information was performance
status (Voest et al., 1989). In order to make some ass t
of this effect, the data have been reanalysed omitting patients
dying in the first month (i.e. those most likely to be of poor
performance status). The relative hazard ratio associated with
referral to a joint clinic still remains significnt (RHR = 0.68,
P<0.01). Problems ofstaging due to inadequately recorded
information on the emination at laparotomy or investiga-
tions are also recognised.
Because this study included all patients diagnosed in Scot-
land it was unbiased in patient selection and provides a valid
database for examining the genrality of treatment in ovarian
cancer.
The age distribution of patients in this cohort was similar
to other population-based studies (Ries et al., 1991; Hogberg
et al., 1993), as was stage and degree of histological
differentiation (Hogberg et al., 1993). Histological type dist-
ribution is not dissimilar to reports in the literature (Mal-
kasian et al., 1975). One other large series of 726 cases
(Omura et al., 1991) reports the piese of ascites to be a
significantly detrimental prognostic indicator. In our study,
the presence of ascites was a strong and idependent prog-
nostic factor (P<0.001) and should be considered in future
studies.
The report on accptable practie in ovarian cancer man-
agement crculated to gynaecologists and surgeons in Scot-
land in 1992 (Management of Ovarian Cancer, 1991) could
not have affected our resuls as this study refers to patients
treated 4 years prior to its publication in 1991.
The effect of treatment in teaching hospitals is not statis-
ticlly signnt in this study. The relative hazard ratio
(RHR) for non-teaching compared with teaching hospitals is
1.19 using Cox's proportional hazards model and adjusting
for the prognostic factors age, stage, degree ofdifferentiation,
pathological type and presnce of ascites. However, this
hazard ratio is similar in size to that found in a larger study
of 3,000 cases diagnosed between 1975 and 1987 (Hole &
Gillis, 1993), which produced a RHR of 1.13 and was statis-
tically sigificant. We believe that the non-significnt finding
in this study is due to insufficient numbers of patients to
detect such a difference rather than being evidence of there
not being an effect.
-The effect of being operated on by a specialist gynae-
cologist also shows the possibility of benefit (RHR = 0.86),
though this is not statistically significant. We believe it will
need a larger number of cases than the 76 patients who were
operated on by specialist gynaecologists in this study to
determine whether this effect is real.
Tlhe first four clinical management factors found to affect
survival agree with those published in the Department of
Health report on ovarian cancer (Management of Ovarian
Cancer, 1991). Our results give weight to the report and
encouragement for its use in the management of ovarian
cancer. The fifth, improvement insurvival with multidiscip-
linary management, is a new finding. The data presented in
this report indicate that for a number ofwomen with ovarian
cancer inScotland in 1987 the outcome of treatment could
have been improved by changes in the organisation and
delivery of that treatment. Purchasers may wish to stipulate
that the management of patients with ovarian cancer should
include the factors outlined in this paper. The findings of this
study have been presented to all consultant gynaecologiss in370 EJ. JUNOR et al.
Scotland and the Chief Medical Officer for Scotland has
commissioned a multidisciplinary group to formulate guide-
lnes (including referral routes as well as treatment) for the
managet of patients with ovarian cancer in Scotland.
Only prospective audit will show whether acceptance and
adherence to the guideline results in improved survival on a
population basis.
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